A Sarasota biotech company received notice from the New York Stock Exchange this week that it is out of compliance with the organization’s listing standards.
Oragenics is not in compliance with the NYSE requirements that stockholders’ equity total at least $4 million if the company has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years and $6 million in its five most recent fiscal years, according to a statement.
(Oragenics, in a Monday SEC filing on the situation, listed 1990 Main St., Sarasota, in the Regus shared and co-work office space, as the address of its principal executive officers. That's a change from previous corporate filings that listed the corporate address in Tampa. Oragenics was founded in 1996.)